Thomas C. Seoh
Directeur Général chez Kinexum Development LLC
Profil
Thomas C.
Seoh is currently the President & Chief Executive Officer at Kinexum Development LLC since 2017.
Previously, he worked as the Chief Executive Officer at Domain Therapeutics SA from 2006 to 2008.
He also held positions as Director at Arbios Systems, Inc., Senior VP-Corporate & Commercial Development at Guilford Pharmaceuticals, Inc., and President at NexGen Medical Systems, Inc. Mr. Seoh received his undergraduate and graduate degrees from Harvard University.
Postes actifs de Thomas C. Seoh
| Sociétés | Poste | Début |
|---|---|---|
| Kinexum Development LLC | Directeur Général | 27/04/2017 |
Anciens postes connus de Thomas C. Seoh
| Sociétés | Poste | Fin |
|---|---|---|
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | President | 01/12/2008 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | 03/10/2005 |
NexGen Medical Systems, Inc.
 NexGen Medical Systems, Inc. Medical SpecialtiesHealth Technology NexGen Medical Systems, Inc. develops medical devices that enhance the safety and effectiveness of interventional procedures in patients with debilitating neurological and cardiovascular diseases. The firm focuses on commercializing an integrated medical device product line for removal of blood clots from head, neck, and peripheral vessels. The company was founded by Richard E. Latchaw, John Kucharczyk and George T. Gillies and is headquartered in Wayzata, MN. | President | - |
| ARBIOS SYSTEMS, INC. | Directeur/Membre du Conseil | - |
Formation de Thomas C. Seoh
| Harvard University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Arbios Systems, Inc.
 Arbios Systems, Inc. Medical SpecialtiesHealth Technology Arbios Systems, Inc. engages in the development, manufacture, and marketing of liver assist therapies for medical treatment of liver failure. The company was founded by Achilles A. Demetriou and Jacek Rozga in February 1999 and is headquartered in Allendale, NJ. | Health Technology |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
| Kinexum Development LLC | Miscellaneous |
NexGen Medical Systems, Inc.
NexGen Medical Systems, Inc. Medical SpecialtiesHealth Technology NexGen Medical Systems, Inc. develops medical devices that enhance the safety and effectiveness of interventional procedures in patients with debilitating neurological and cardiovascular diseases. The firm focuses on commercializing an integrated medical device product line for removal of blood clots from head, neck, and peripheral vessels. The company was founded by Richard E. Latchaw, John Kucharczyk and George T. Gillies and is headquartered in Wayzata, MN. | Health Technology |
